Physician profile
Brian D Buchanan
NPI 1356315980
$1,144.74
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $481 · 2021: $282 · 2022: $55.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $286.58 | 2019-2022 | |
| Amarin Pharma, INC. | $230.74 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $107.39 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $96.58 | 2019-2022 | |
| Pfizer INC. | $93.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $72.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.13 | 2021 | |
| Novo Nordisk INC | $44.14 | 2019-2021 | |
| Amgen INC. | $31.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.44 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.16 | 2021 | |
| Abbvie INC. | $15.30 | 2020 | |
| Merck Sharp & Dohme LLC | $14.12 | 2020 | |
| Glaxosmithkline, LLC. | $13.73 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.38 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $11.85 | 2022 | |
| Biogen, INC. | $11.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.